Kalypsys recognizes the value and importance of working in a collaborative partnership that utilizes epiK™.
We encourage you to explore the possibilities.
Product Partnerships
Kalypsys is interested in a partnership to advance the following compounds to late stage trials and commercialization:
NOS [KD7040, kD7332]
KD7040 is a topically administered iNOS inhibitor. an IND was filed in 4Q 2006 and a Phase IIa clinical proof of concept trial in patients with post herpetic neuralgia was completed in late 2008. Kalypsys recognizes the potential to expand the indication range by study of KD7040 in carpel tunnel syndrome.
KD7332 is an oral iNOS/nNOS dual inhibitor with indications in neuropathic pain. IND-enabling GLP safety pharmacology and toxicology studies are presently in progress.
ppar delta [kd3010]
KD3010 is an orally administered PPARδ specific agonist. An IND was filed in 2Q 2006 with Phase Ia and Phase Ib clinical trials completed in 2008. KD3010 is Phase II ready with potential in Diabetes Mellitus and Non-Alcoholic Steatohepatitis (NASH).
gpr119
Kalypsys has proprietary GPR119 selective agonists that demonstrate antidiabetic activity in late stage optimization.
Please visit our Partnering page for additional information to discuss opportunities in this space.
Kalypsys Systems
Kalypsys offers our proprietary technology and informatics solutions through our Kalypsys Systems business unit. This suite of products provides an avenue for increased productivity and reliability that is unmatched in the area of automated drug discovery.
FOR MORE INFORMATION CONTACT:
Discovery and Product Partnerships
Jackie Gulick
+1 (858) 754-3397
jgulick@kalypsys.com
Systems Sales
Paul Queeney
+1 (858) 754-3376
pqueeney@kalypsys.com